Ipsen's Stock Hits a New Historical Record, Surpassing 162 Euros

Record-Breaking Performance

Ipsen reached an unprecedented peak of 162.20 euros during the trading session on February 27, exceeding the previous ceiling set on February 26 at the same level. This breakthrough occurs in a context of a sustained upward dynamic for several weeks. The price is now significantly above its 50-day moving average, which is at 135.15 euros, representing a gap of more than 19%. This significant distance from this trend indicator reflects the strength of the ongoing movement. Concurrently, the Relative Strength Index (RSI) stands at 90, a level indicating a pronounced overbought zone. This indicator, which oscillates between 0 and 100, reflects the speed and magnitude of the recent rise. Such positioning indicates that the stock has experienced a marked acceleration and is in an extreme technical configuration, without necessarily predicting a reversal. The nearest technical resistance was precisely at 160.50 euros, now surpassed, potentially paving the way for new levels.

Consistent Performance Across Timeframes

Ipsen's performance stands out for its consistency across different timeframes. Over seven days, the stock has gained 1.77%, while the increase reaches 28.8% over three months and 45.83% over a year. This trajectory places the biopharmaceutical group among the most successful stocks in the Paris-listed healthcare segment. The monthly volatility remains contained at 8.09, and the stock's beta, measured at 0.03, indicates an almost total decoupling from the general market fluctuations. This defensive profile historically characterizes pharmaceutical laboratories with recurring revenues related to established medical specialty portfolios. Ipsen, whose activities are primarily focused on oncology, neuroscience, and rare diseases, benefits from this visibility on its revenue streams. The stock was trading at 110.30 euros a year ago, illustrating the significant progress made by the stock on Euronext Paris over twelve months.